TRCT
XRTX

Tower Research Capital (TRC)’s XORTX Therapeutics XRTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17
Closed -$138 – 6051
2024
Q3 		$138 Buy
+17
New +$145 ﹤0.01% 5474

Other funds holding XRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

Tower Research Capital (TRC)'s XRTX Position: Q4 2024 in Review

Tower Research Capital (TRC) sold out of XORTX Therapeutics (XRTX) in Q4 2024, closing a stake of 17 shares — an estimated $138 sold.

Tower Research Capital (TRC) first reported a position in XRTX in Q3 2024 and held it in 1 quarter. The position peaked at $138 in Q3 2024. 6 funds tracked by Wall St. Rank hold XRTX as of Q4 2024.

  • Tower Research Capital (TRC) reported no remaining XORTX Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 17 XORTX Therapeutics shares in Q4 2024, an estimated $138.
  • Tower Research Capital (TRC) first reported a position in XORTX Therapeutics in Q3 2024 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s XORTX Therapeutics position peaked at $138 in Q3 2024.
  • 6 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q4 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.